Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia

Cancer

Volumn 120, Issue 3, 2014, Pages 451-452

  Gozzetti, Alessandro ^a   Defina, Marzia ^a   Fabbri, Alberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

AGED; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER GRADING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; HUMAN; INCIDENCE; INFECTION COMPLICATION; LETTER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PANCYTOPENIA;

EID: 84892919297     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28443     Document Type: Letter

References (8)

1. Strati P, Wierda W, Burger J, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia [published online ahead of print August 13, 2013]. Cancer. doi: 10.1002/cncr.28318.
2. Foon KA, Mehta D, Lentzsch S, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012; 119: 3184-3185.
3. Bocchia M, Bigazzi C, Marconcini S, et al. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas. Haematologica. 1999; 84: 716-720.
4. Marotta G, Bigazzi C, Lenoci M, et al. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia. Haematologica. 2000; 85: 1268-1270.
5. Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J. 2004; 5: 472-474.
6. Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol. 2007; 139: 90-93.
7. Forconi F, Fabbri A, Lenoci M, et al. Low-dose fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic leukemia. Haematol Oncol. 2008; 26: 247-251.
8. Fabbri A, Cencini E, Rigacci L, et al. Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas [published online ahead of print July 22, 2013]. Leuk Lymphoma.